Latest News and Press Releases
Want to stay updated on the latest news?
-
EXTON, PA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management...
-
EXTON, PA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities,...
-
EXTON, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its first annual chart audit study in hematology, Patient Chart Dynamix™ : Paroxysmal Nocturnal Hemoglobinuria (PNH)...
-
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
-
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
-
EXTON, PA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa,...
-
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
-
EXTON, PA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care...
-
EXTON, PA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for...
-
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...